

RIGHT PATIENT RIGHT TREATMENT RIGHT TIME

Expanding the Reach of Targeted Therapy in ADVANCED NSCLC

Monday, 22 November 2021 | 19:30 – 21:00 (SGT) | Channel 2



FACULTY

Daniel S.W. Tan

MBBS, MRCP, PhD, FAMS (Chair)
National Cancer Centre Singapore
Singapore, Singapore

Keith Kerr

BSc, MB ChB, FRCPath
Aberdeen Royal Infirmary
Aberdeen, Scotland

Byoung Chul Cho, MD, PhD

Yonsei Cancer Center
Yonsei University College of Medicine
Seoul, South Korea

YongFeng Yu, MD

Shanghai Chest Hospital
Jiao Tong University
Shanghai, China

This educational activity is supported by an independent grant from the Healthcare business of Merck KGaA, Darmstadt, Germany

AGENDA

Welcome and introduction | *Daniel S.W. Tan, MBBS, MRCP, PhD, FAMS*

Identifying the “right patient”: Expanding the role of NGS in detecting rare alterations in advanced NSCLC | *Keith Kerr, BSc, MB ChB, FRCPath*

Panel discussion: Challenges in genomic profiling and interpretation of results | *Moderated by Daniel S.W. Tan, MBBS, MRCP, PhD, FAMS*

PROVIDING “THE RIGHT TREATMENT AT THE RIGHT TIME”

Case #1 - Advanced EGFR-mutant NSCLC progressing on first-line osimertinib | *YongFeng Yu, MD*

Panel discussion: Identifying and tackling EGFR TKI resistance in daily practice | *Moderated by Daniel S.W. Tan, MBBS, MRCP, PhD, FAMS*

Case #2 - Advanced NSCLC with MET ex 14 skipping mutation and PD-L1 expression | *Byoung Chul Cho, MD, PhD*

Panel discussion: Treatment sequencing in patients with rare driver mutations | *Moderated by Daniel S.W. Tan, MBBS, MRCP, PhD, FAMS*

Ask the experts

Pearls for practice | *Daniel S.W. Tan, MBBS, MRCP, PhD, FAMS*